Three-arm randomized phase II study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)

BACKGROUND: Pre-clinical evidence supports the clinical investigation of inhibitors to the insulin-like growth factor receptor (IGFR) and the epidermal growth factor receptor (EGFR) alone and in combination in patients with NSCLC. PATIENTS AND METHODS: Patients with chemotherapy-naïve, advanced NSCL...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Hanna, Nasser H., Dahlberg, Suzanne E., Kolesar, Jill, Aggarwal, Charu, Hirsch, Fred R., Ramalingam, Suresh S., Schiller, Joan H.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4560671/
https://ncbi.nlm.nih.gov/pubmed/25740387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29308
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars